Eli Lilly’s diabetes medication Mounjaro has continued to experience robust sales growth despite supply challenges, with the GLP-1/GIP agonist generating $1.4 billion in global sales for the third quarter. This marks a 44% increase from the previous quarter and surpasses Wall Street predictions by 15%. While demand remains strong, sales could have been higher if … Read more
Eli Lilly, the pharmaceutical giant, is intensifying its legal efforts to combat unauthorized versions of its popular diabetes drug, Mounjaro. In September, the company filed lawsuits against eight US entities for producing or selling compounded versions of the drug. Now, just a month later, Lilly is expanding its campaign by targeting 11 online pharmacies, several … Read more
The soaring demand for new anti-obesity medications has led to a concerning trend, with various online companies attempting to sell these “must-have” drugs without proper approval or prescription, prompting the FDA to take action. The FDA recently issued warning letters to two companies, Semaspace and Gorilla Healing, instructing them to cease selling online versions of … Read more
Eli Lilly is undergoing leadership changes in its diabetes and obesity division as it anticipates a significant FDA decision in the obesity field. After 34 years with the company, Mike Mason, president of Lilly Diabetes and Obesity, is retiring and will be succeeded by Patrik Jonsson on January 1. Patrik Jonsson, a 33-year veteran at … Read more
The surging demand for GLP-1 diabetes and weight loss medications has led to an inevitable influx of knockoff versions. Earlier this summer, Novo Nordisk took legal action against several companies for manufacturing and selling compounded variants of Ozempic and Wegovy. Now, Eli Lilly has followed suit, initiating legal proceedings against firms accused of marketing unauthorised … Read more
Eli Lilly’s diabetes medication, Mounjaro (tirzepatide), has been on a winning streak since its US launch in May, and now it’s poised for a significant boost in the United Kingdom. England’s National Institute for Health and Care Excellence (NICE) has given its green light to Mounjaro for the treatment of poorly controlled Type 2 diabetes … Read more
As Eli Lilly’s flagship diabetes medication, Mounjaro, continues its meteoric rise in popularity and edges closer to potential approval for obesity treatment, the company remains undeterred by supply challenges and recent trial outcomes from Novo Nordisk’s well-established weight loss drug, Wegovy. Eli Lilly’s GIP/GLP-1 agonist, Mounjaro, is experiencing remarkable demand, evident by its second-quarter sales … Read more
Eli Lilly has received positive data for its experimental obesity therapies, but in the UK, it faced a setback as the cost-effectiveness watchdog NICE rejected the use of Mounjaro as a treatment for type II diabetes. According to NICE, more evidence is needed regarding the clinical benefits and cost-effectiveness of Mounjaro (tirzepatide) before it can … Read more
Eli Lilly is aggressively pursuing advancements in the field of obesity treatment, accelerating the development of an oral medication option alongside a range of supplementary therapies. Currently, the pharmaceutical giant is propelling forward with the development of orforglipron, an oral drug candidate, exploring new dosage options for tirzepatide—marketed as Mounjaro for diabetes—and nurturing early-stage candidates … Read more
Since the FDA gave the green light to Novo Nordisk’s GLP-1 weight-loss medication Wegovy over two years ago, the drug has been a focal point of anticipation for analysts and investors. Novo’s financial disclosures for the third quarter provide a more detailed picture of this blockbuster’s performance. In the first nine months of 2023, Novo … Read more
Eli Lilly, known for its weight loss contender Mounjaro, is making strides in the immunology arena. The FDA has granted approval to Lilly’s mirikizumab, marketed as Omvoh, making it the first IL-23 inhibitor to enter the competitive ulcerative colitis landscape, where it joins established biologics from AbbVie, Johnson & Johnson, and Takeda. This recent approval … Read more
As Novo Nordisk grapples with the challenges posed by illicit sales of semaglutide, authorities in the UK and Europe have issued warnings regarding counterfeit Ozempic pens being discovered in the region. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) confirmed the identification of pre-filled pens falsely labeled as Novo’s Ozempic (semaglutide 1mg) at two … Read more
Eli Lilly is actively expanding its involvement in the burgeoning field of antibody-drug conjugates (ADCs) in Europe. Following its recent acquisition of Emergence Therapeutics, Lilly has now sealed a deal to purchase one of its collaborators, Mablink Bioscience, further fortifying its portfolio with advanced ADC technology and a promising pipeline of drug candidates. Lilly’s engagement … Read more
Eli Lilly, which had set ambitious plans to introduce four new drugs in 2023, has faced another setback on the regulatory front. The FDA has declined approval for Lilly’s investigational treatment for atopic dermatitis, lebrikizumab, citing issues discovered during an inspection of a third-party contract manufacturing organization. This recent development marks the third rejection for … Read more
In the realm of diabetes management, a symbiotic relationship appears to be flourishing between Continuous Glucose Monitoring (CGM) technology and GLP-1 drugs, according to a recent analysis conducted by Abbott. The study delves into the usage trends of Abbott’s FreeStyle Libre CGM technology and the increasingly popular GLP-1 drugs developed by pharmaceutical giants like Novo … Read more
Structure Therapeutics has offered an initial glimpse into the effectiveness of its oral GLP-1 receptor agonist, reporting a notable 5% reduction in weight among participants after just four weeks of use. This development generated significant interest, with Structure successfully completing a $185 million IPO earlier this year. The company’s leading candidate is an oral small … Read more
A recent survey of 100 doctors in the United States who prescribe weight loss medications has revealed that over 75% of them consider the new GLP-1 drugs from Eli Lilly and Novo Nordisk to be “paradigm shifting.” These drugs, including Lilly’s tirzepatide and Novo’s semaglutide drugs Ozempic and Wegovy, have seen skyrocketing demand in the … Read more
The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short term. Novo’s recent success with Wegovy, particularly its positive impact on heart health, has opened up significant market potential. Analysts at J.P. Morgan predict that by 2030, Novo could capture nearly half of the market, … Read more
Novo Nordisk’s semaglutide and AstraZeneca’s Farxiga assuming the roles of formidable contenders. The arena is no longer confined to blood sugar control; it now extends into the realm of heart health. As these two pharmaceutical titans stride forward, their strategies and successes are sparking conversations that ripple through medical corridors and boardrooms alike. The European … Read more
Boehringer Ingelheim is forging ahead with its obesity drug candidate, survodutide, moving it into a Phase III program following promising results from a Phase II trial. Developed in partnership with Zealand Pharma and also known as BI 456906, this glucagon/GLP-1 receptor dual agonist demonstrated remarkable potential, achieving up to 19% weight loss in individuals grappling … Read more
As the COVID-19 pandemic surged and waned, the biopharmaceutical industry witnessed a rollercoaster ride of revenue spikes and troughs. However, a sense of stability seems to be returning to pharma sales, with the exception of those manufacturers delving into next-generation treatments for obesity and diabetes. Amid the release of second-quarter financial results, the spotlight shines … Read more
Source – Novo Nordisk Novo Nordisk has been capitalizing on the momentum generated by its weight loss drug, Wegovy, which made a splash in the market in 2021, garnering significant attention and even facing occasional supply shortages. However, a pivotal cardiovascular outcomes trial has the potential to significantly alter the landscape for this emerging medicine. … Read more
In July, AbbVie’s Skyrizi maintained its position as the top pharma drug ad spender for the second consecutive month, but the overall spending on pharmaceutical drug ads witnessed a sharp decline. Skyrizi, one of AbbVie’s successful Humira follow-ups and a major immunology blockbuster, is on track to compete for the 2023 crown, leading the charts … Read more
As Novo Nordisk and Eli Lilly enjoy significant sales from their GLP-1 diabetes and obesity drugs, they also face legal challenges from new users of these medications. One such case involves a Louisiana woman, Jaclyn Bjorklund, who is suing both companies. She claims that her use of Novo’s Ozempic (semaglutide) and Lily’s Mounjaro caused her … Read more
Source – Eli Lilly Eli Lilly continues to gather strong evidence supporting the effectiveness of tirzepatide, its dual GIP/GLP-1 agonist, as a potent weight loss treatment. Known as Mounjaro when used for its approved indication in type 2 diabetes, tirzepatide demonstrated remarkable weight loss results in two trials, Surmount-3 and Surmount-4. Participants in these trials … Read more
Weight Loss Medication: Obesity rates in the United States have significantly increased since the 1980s, with a staggering 41.9% of adults classified as obese as of 2020, according to the CDC. This obesity epidemic has led to a higher risk of various health problems such as heart disease, hypertension, joint pain, and certain types of … Read more
Despite the considerable excitement surrounding the potential of new and potent obesity medicines, these drugs remain inaccessible to many Americans who could greatly benefit from them. One key reason for this limitation is that existing laws prevent Medicare from covering obesity drugs. However, a group of lawmakers, supported by organizations such as Novo Nordisk, Eli … Read more
Due to a shortage of Novo Nordisk’s popular obesity medicine Wegovy, there has been a surge in demand for their first-generation weight-loss drug, Saxenda. Consequently, Novo Nordisk is now facing difficulties in handling the increased demand for Saxenda. According to an update on the FDA’s drug shortage list posted recently, Saxenda will have limited availability … Read more
Following reports of two cases of suicidal thoughts and one case of self-harm among users in Iceland, the European Medicines Agency (EMA) has initiated a review of Novo Nordisk’s diabetes and obesity drugs. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) will investigate Novo’s products Ozempic (semaglutide) and Saxenda (liraglutide) to determine if there is a … Read more
The increased inspection of GLP-I therapies by the European Medicines Agency (EMA) has raised a warning about the possibility that the diabetes and obesity medications might lead to cancer. The action is the regulator’s first step towards tracking any potential adverse occurrences that could be connected to the usage of licenced medications. According to Novo … Read more
pharmtales
Latest Pharma News & Insights
